Jennifer A. Marks, MD (@jennifermarksmd) ranks #28 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 5 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: DESTINY-Lung04, ARROS-1, ADAURA. CMS Open Payments lists $21,424 in 2025 general payments.
At a Glance
- 7 posts naming a trial in 2026
- 8 trials discussed by name
- Lung Cancer: US #28 · 5 physicians engaged
- Presented at Best of ASCO Yellowstone 2026 in 2026
- CMS Open Payments lists $21,424 in 2025 general payments.
This Month
What Jennifer A. Marks, MD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Jennifer A. Marks, MD
Physicians who reposted Jennifer A. Marks, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #28 | — | 5 | 9 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Jennifer A. Marks, MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- Best of ASCO Yellowstone 2026 · Invited lectureUpdates in advanced NSCLC (incl. HARMONi-6, WU-KONG28, OptiTROP-Lung05)Source: @Joshua_Reuss on X ↗
What Colleagues Are Saying About Jennifer A. Marks, MD
2026 posts by fellow physicians that mention @jennifermarksmd, quoted word for word.
Dr. @jennifermarksmd presents updates in adv NSCLC at Yellowstone 2026 Best of @ASCO including HARMONi-6, WU-KONG28 and OptiTROP-Lung05. Will be impt to see how these agents perform in global studies and in case of sunvo, would just like ACCESS to drug! Hopefully coming soon!! https://t.co/BtDvg1flYb
Trials Jennifer A. Marks, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| DESTINY-Lung04 | 1 | #9 of 37 | Sep 14, 2026 |
| ARROS-1 | 1 | #23 of 26 | Sep 14, 2026 |
| ADAURA | 1 | #27 of 41 | Sep 13, 2026 |
| MAVERICK (SWOG S1827) | 1 | #18 of 33 | Sep 12, 2026 |
| LIBRETTO-432 | 1 | #43 of 53 | May 31, 2026 |
| RASolute 302 | 1 | #49 of 73 | May 31, 2026 |
| HARMONi-6 | 1 | #55 of 74 | May 31, 2026 |
| WU-KONG28 | 1 | #20 of 29 | May 29, 2026 |
Jennifer A. Marks, MD on DESTINY-Lung04
Dr. @JuliaRotow presents DESTINYLung04, 1L T-DXd in HER2 mt NSCLC. Study met its primary endpoint of mPFS, 14.3 vs 8.3 mo, HR 0.63; P<0.0001. No OS benefit but durability and response favored T-DXd. ILD and ♥️ AEs require awareness and close monitoring @IASLC #WCLC26 #LCSM https://t.co/615R1IXBwO
Jennifer A. Marks, MD on ARROS-1
Dr. Malinda Itchins reviews the ARROS-1 trial and where zida fits into @ros1cancer space. Several options but zida appears to be the winner in terms of tolerability. @IASLC #WCLC26 #lcsm https://t.co/PbkPZyAJS7
Jennifer A. Marks, MD on ADAURA
ADAURA 8-yr OS update continues to show an OS benefit 92 mo vs 68.5 mo, HR 0.53, with most profound benefit in stage IIIA. @IASLC @EGFRResisters #WCLC26 @DrRoyHerbst https://t.co/yBK0Ld6xwJ
Jennifer A. Marks, MD on MAVERICK (SWOG S1827)
Biggest take away from SWOG S1827/MAVERICK trial - MRI surveillance alone resulted in improved cognitive failure free survival (HR 0.60, 90% CI 0.46-0.78, p=0.0005) in #SCLC Should we then be following disease with q3mo MRIs or at least q6mo for all? #WCLC26 #lcsm @IASLC https://t.co/FzdN2xUpc3
Jennifer A. Marks, MD on LIBRETTO-432
RT @M_Torasawa: 📘 LIBRETTO-432 — NEJM https://t.co/yIPxmCSXKt 📗 HARMONi-6 — The Lancet https://t.co/M5ddl03tSu 📘 RASolute 302 — NEJM http…
Jennifer A. Marks, MD on RASolute 302
RT @M_Torasawa: 📘 LIBRETTO-432 — NEJM https://t.co/yIPxmCSXKt 📗 HARMONi-6 — The Lancet https://t.co/M5ddl03tSu 📘 RASolute 302 — NEJM http…
Jennifer A. Marks, MD on HARMONi-6
RT @FordePatrick: Impressive results from the phase 3 Harmoni 6 trial of chemotherapy plus ivonescimab or anti-PD1 for advanced squamous lu…
Jennifer A. Marks, MD on WU-KONG28
WU-KONG28 (1L sunvozertunib vs chemo) showed improved PFS2 of 21.7 vs 15m (OS immature) with prolonged DoR (11.2 v 7mo). CPK elevation seen in 20%. @ASCO #lcsm #lcsm #ASCO26 https://t.co/EKLoTPPntj
Jennifer A. Marks, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Always love to see a drug beating topotecan. For #sclc. Tam-Peli (B7-H3 ADC) vs topotecan showed OS benefit (13.3 m vs 9.4 m, HR 0.46) with CNS efficacy. Safety profile seems a bit intense. High number of grade 3 or higher, most commonly hematologic. @IASLC #WCLC26 #ADC #lcsm https://t.co/4lQvjaAbjy
SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer - Lung Cancer https://t.co/QPK49yPajx #lcsm #lcam #egfr @SclcSMASHERS @EGFRResisters @IASLC https://t.co/JiDxaPa0GY
If only I had signed up in time for the talent show in at @IASLC #WCLC26 … #lcsm #golden #kellyclarkson https://t.co/yOSX0KtUO6
#TexasLung26 Hold ‘Em Debate @TLCconference #lcsm @IASLC https://t.co/5AL2h3Dznv
So proud of Andrew Moriarty @AMoriarty24 of @DFarberThoracic for presenting our updated collaborative work with @NeoGenomics in HER2 altered #NSCLC. #WCLC26 @IASLC #lcsm Thanks for featuring, @OncLive ! https://t.co/CDa2wdWu5d
Industry Payments
CMS Open Payments · 2025 general payments
$21,424 across 25 payments